You are here
SUNY Upstate Medical University Selects iCAD’s Xoft Electronic Brachytherapy System for Early-Stage Breast Cancer Treatment
Premier center becomes first in the region to offer intraoperative radiation therapy with the leading-edge Xoft System to advance quality patient care in New York State
NASHUA, N.H. and SYRACUSE, N.Y., Oct. 09, 2018 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that its Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is now available at Upstate Medical University. Affiliated with the State University of New York, Upstate Cancer Center is the first facility in central New York State to offer treatment of early-stage breast cancer using intraoperative radiation therapy (IORT) with the advanced Xoft System. The hospital is the only academic medical center in the area and serves 1.8 million people.
"We are pleased to be the first facility in central New York to use this technology and offer this breakthrough treatment to our patients,” said Lisa Lai, MD, Director of the Breast Cancer Program at the Upstate Cancer Center. “With the adoption of this system, the Upstate Cancer Center now offers a valuable treatment option that significantly benefits early-stage breast cancer patients by providing shorter treatment times, fewer side effects, reduced costs and improved quality of life.”
The Xoft System uses a miniaturized X-ray source to deliver one precise, concentrated dose of radiation to a tumor site at the time of breast-conserving surgery (lumpectomy). The treatment can be completed in as little as eight minutes, making it possible for appropriately selected patients to replace six to eight weeks of traditional radiation therapy with a single treatment. The Xoft System is cleared by the U.S. Food and Drug Administration (FDA), CE marked, and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including early-stage breast cancer, non-melanoma skin cancer, and gynecological cancers. It has been used to successfully treat more than 15,000 patients worldwide.
“Healthcare facilities around the world are increasingly adopting the Xoft System, recognizing the unique benefits this state-of-the-art technology offers to both patients and clinicians in the fight against cancer,” said Ken Ferry, CEO of iCAD. “New York is one of the states with the highest breast cancer incidence rates, with approximately 15,000 New Yorkers being diagnosed annually. We are pleased to join with SUNY Upstate Medical University to provide unprecedented access to this important treatment option to patients in New York State.”
A recent study established that IORT with the Xoft System is clinically proven to be the preferred method of treatment for early-stage breast cancer as compared to external beam radiation therapy due to significant cost savings, reduced radiation exposure and improved quality of life. The research demonstrated a direct cost savings of $630 million annually for the U.S. healthcare system and $10,500 per breast cancer patient annually over the lifetime of a patient.
The new IORT treatment solution with the Xoft System is available at the Upstate Cancer Center at SUNY Upstate Medical University. Patients interested in learning more about IORT can call 1-855-964-HOPE (4673) to schedule an appointment.
About iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “would”, “could”, “consider”, “project”, “estimate”, “will”, “continue”, “anticipate”, “likely”, “seek”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, including the 10-K for the year ended December 31, 2017, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
ARPR, on behalf of iCAD, Inc.
Paul Barren, (855) 300-8209
SUNY Upstate Medical University:
Darryl Geddes, (315) 464-4828
LifeSci Advisors, on behalf of iCAD, Inc.
Jeremy Feffer, (212) 915-2568